Optimi Health Announces Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - August 7, 2024) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a GMP-approved, Health Canada licensed psychedelics pharmaceutical manufacturer specializing in botanical psilocybin and MDMA, announces it intends to complete a non-brokered private placement of up to 16,666,666 units (each a "Unit") at CAD$0.30 per Unit for gross proceeds of up to CAD$5,000,000 (the "Offering"). Each Unit comprised of one...
2024-08-07 8:30 AM EDT
Optimi Health to Enter Asian Market with PsiloThai Collaboration on Psilocybin Research
Vancouver, British Columbia--(Newsfile Corp. - July 23, 2024) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a GMP-approved, Health Canada licensed psychedelics pharmaceutical manufacturer specializing in botanical psilocybin and MDMA, is pleased to announce a strategic supply partnership and Letter of Intent with PsiloThai, a leading patient advocacy group registered in Thailand. This agreement marks a significant milestone as Optimi becomes the...
2024-07-23 8:30 AM EDT
Optimi Health and Mind Medicine Australia Launch OptiMed Prescriber Portal for Australian Psychiatrists
Vancouver, British Columbia--(Newsfile Corp. - June 27, 2024) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Health Canada-approved, GMP-compliant pharmaceutical drug manufacturer specializing in the controlled substances MDMA and botanical psilocybin, is pleased to announce the launch of OptiMed, an online prescriber portal designed to provide Australian psychiatrists with comprehensive resources and support for prescribing psychedelic medicines...
2024-06-27 8:30 AM EDT
Health Canada Issues Three Export Permits to Optimi to Supply Patients Under Australia's Authorised Prescriber Scheme
Vancouver, British Columbia--(Newsfile Corp. - June 25, 2024) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Health Canada-approved, GMP-compliant pharmaceutical drug manufacturer specializing in the controlled substances MDMA and botanical psilocybin, is pleased to announce that it has received the three necessary export permits from Health Canada to supply GMP MDMA and psilocybin capsules for use in patients participating in Australia's Authorised...
2024-06-25 8:30 AM EDT
Optimi Health Completes First International Shipment of MDMA to Israel and Secures CBSA Exporters Authorization ID
Vancouver, British Columbia--(Newsfile Corp. - June 11, 2024) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a leading Health Canada licensed GMP psychedelics pharmaceutical manufacturer, specializing in controlled substances such as botanical psilocybin and MDMA, is pleased to announce a series of milestones in its international psychedelic supply operations and corporate marketing strategy. Optimi has completed its first international shipment to...
2024-06-11 8:30 AM EDT